Scientists have unveiled a strategy for targeting a vulnerability in tiny circles of floating DNA that can drive aggressive cancers. These circles — known as
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Can Illumina win over labs that have never tried DNA sequencing? The company on Wednesday unveiled what it called its simplest machines yet for parsing
A gene therapy pioneer thinks he has a solution to the field’s struggle to commercialize breakthrough cures: Go global. Jim Wilson’s Philadelphia-based company GemmaBio on
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
To increase the pace of rare disease drug approvals, the FDA should embrace nontraditional data, deploy new forms of analysis and be more open about